QLT Inc. (QLTI) Announces Positive Preliminary Results From Phase 1b Retreatment Trial Of QLT091001 In Subjects With Leber Congenital Amaurosis And Retinitis Pigmentosa Due To Mutations In LRAT Or RPE65
2/27/2014 9:43:36 AM
VANCOUVER, British Columbia, Feb. 27, 2014 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced positive preliminary results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT).
Help employers find you! Check out all the jobs and post your resume.
comments powered by